Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Summary not available.
Pacira BioSciences (Nasdaq:PCRX) will join analyst-led fireside chats at three major healthcare conferences in May and June 2026: RBC Capital Markets, Jefferies, and Goldman Sachs. Live audio webcasts and two-week replays will be available on the company’s investor website under the Events section.
Pacira BioSciences (Nasdaq:PCRX) sent a letter urging stockholders to support its three board nominees ahead of the June 9, 2026 Annual Meeting. The company highlights its 5x30 growth strategy and emphasizes nominees’ experience in government, drug development, M&A, commercialization and biopharmaceutical leadership.
Pacira argues DOMA’s alternate slate lacks relevant public biopharma and board experience and could harm long-term stockholder value.
Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on May 4, 2026 to ten new employees under its Amended and Restated 2014 Inducement Plan as permitted by Nasdaq Listing Rule 5635(c)(4).
The Committee approved options for an aggregate of 36,800 shares and restricted stock units for 27,700 shares. Options carry a 10-year term, four-year vesting; RSUs vest annually over four years beginning May 4, 2027, and awards use a $24.69 exercise price for options.
Summary not available.
Pacira BioSciences (Nasdaq: PCRX) reported Q1 2026 results: $177.4M total revenue (+5% vs. Q1 2025), GAAP net income of $2.9M ($0.07/share), and non-GAAP net income of $24.5M ($0.60/share). Adjusted EBITDA was $40.2M. The company completed enrollment in a Phase 3 ZILRETTA shoulder OA study and repurchased 2.2M shares for $50.0M. Pacira reiterated full-year 2026 guidance, including EXPAREL sales $600M–$620M and total revenue $745M–$770M.
Pacira BioSciences (NASDAQ: PCRX) filed definitive proxy materials for its June 9, 2026 Annual Meeting and mailed a shareholder letter urging a vote “FOR” the company’s three nominees on the BLUE proxy card. The company highlights its 5x30 strategy, >35% stock gain since launch, 2025 operational milestones, patent estate expansion, $200M+ share repurchases, and upcoming 2026 clinical and registrational readouts.
Pacira BioSciences (NASDAQ: PCRX) presented a retrospective Medicare real‑world study showing EXPAREL (bupivacaine liposome) was associated with lower opioid consumption, reduced healthcare utilization, and lower total medical costs versus non‑liposome bupivacaine after outpatient total hip arthroplasty over 12 months.
Key results: reduced MMEs at 30/90/180/365 days, fewer inpatient admissions and outpatient visits, and lower total medical costs at 30/90/180/365 days.
Pacira (Nasdaq: PCRX) will report first quarter 2026 financial results after market close on Thursday, April 30, 2026.
Following the release, Pacira will host a live conference call and webcast at 4:30 p.m. ET; telephone participants must pre-register to receive dial-in information and a PIN. A webcast replay will be available on the company website for about two weeks.
Pacira (NASDAQ: PCRX) presented three real-world HOPD analyses at AMCP 2026 showing EXPAREL (liposomal bupivacaine) was associated with lower or comparable total healthcare costs and reduced opioid use in select cohorts through six months.
Key findings: THA costs were lower at 3 months ($7,332 vs $8,153) and 6 months ($13,022 vs $15,081); TKA showed comparable or lower costs, notably in teaching hospitals; a 3-year budget model projected −$117,868 per 1M members versus ropivacaine.